Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a bi-national cohort analysis

Accepted/In Press date: 1 December 2020

e-pub ahead of print date: 29 December 2020

Published date: 12 June 2021

Additional Information: Funding Information: Funding was provided by Health Technology Assessment Programme Assessment project number 14/36/02. The project was partially funded by Centro de Investigaci?n Biom?dica en Red Fragilidad y Envejecimiento Saludable. Funding Information: Funding was provided by Health Technology Assessment Programme Assessment project number 14/36/02. The project was partially funded by Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable. JP and MJP‐S are supported by PI19/00037 (Spanish Ministry of Health ISCIII FIS‐FEDER) and RD16/0009/0013 (Instituto de Salud Carlos III (ISCIII) FEDER REDinRen). This work was supported by the NIHR Oxford Biomedical Research Centre. AJ was supported by the NIHR Biomedical Research Centre at University Hospitals BristolandWestonNHS Foundation Trust and the University of Bristol. No funder was directly involved in any aspect of this work. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. Funding Information: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: DPA reports grants and other from AMGEN; grants, non‐financial support, and other from UCB Biopharma; grants from Les Laboratoires Servier, outside the submitted work. DPA also reports that Janssen, on behalf of the IMI‐funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs that are organized by DPA's department and are open to external participants. AJ reports personal fees from Freshfields Bruckhaus Derringer and Anthera Pharmaceuticals Inc., outside the submitted work. CC reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB. KJ reports grants from NIHR HTA during the conduct of the study and personal fees from UCB and AMGEN, outside the submitted work. NA reports grants from Merck and personal fees from Merck, Regeneron, Pfizer/Eli Lilly, and Flexion, outside the submitted work. VS reports consultancy fees from Janssen Pharmaceutica NV, during the conduct of the study. XN reports advisory boards for Amgen, Eli Lilly, and Formation, and talks for Amgen, Eli Lilly, FAES, and ITALFARMACO. ADP reports personal fees from AMGEN‐UCB, Eli Lilly, Gilead, and Sandoz; other from Active Life Sci; and personal fees and non‐financial support from EchoLight, outside the submitted work. BA reports institutional research contracts and personal consulting fees from UCB Biopharma sprl, institutional research contracts from Novartis, personal speaker's fees from Eli Lilly and Amgen, and personal consulting fees from Kyowa‐Kirin Plc. CT reports personal fees from Boehringer Ingelheim and Amgen, outside the submitted work. Publisher Copyright: © 2020 American Society for Bone and Mineral Research (ASBMR) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

Keywords: ANTIRESORPTIVES, FRACTURE PREVENTION, GENERAL POPULATION STUDIES, OSTEOPOROSIS, STATISTICAL METHODS

Local EPrints ID: 446303

URI: http://eprints.soton.ac.uk/id/eprint/446303

DOI: doi:10.1002/jbmr.4235

ISSN: 0884-0431

PURE UUID: 0f71957d-c814-46bd-af11-220eb2ad6dd4

ORCID for Cyrus Cooper: orcid.org/0000-0003-3510-0709

Date deposited: 04 Feb 2021 17:30

Last modified: 18 Mar 2024 02:46